BJDX Bluejay Diagnostics, Inc. Insider Trading

HRT Financial (10% owner) bought 64,047 shares at $1.51 and sold 34,938 at $1.40, net +29,109 shares (+46.2%), as BJDX trades 92.2% below 52-week high.

HRT Financial executed 2 separate transactions on consecutive days—a purchase of 64,047 shares at $1.51 on 2026-07-09 and a sale of 34,938 shares at $1.40 on 2026-07-10—resulting in a net addition of 29,109 shares (+46.2% relative to pre-transaction holdings of 62,946 shares). The buys and sells occur at prices within a narrow band, and the net effect is increased exposure. The transaction coincides with severe price erosion: BJDX is trading at $1.30, down 92.2% from its 52-week high of $16.68 and down 73.4% over the prior 30 days. The company faces fundamental challenges, with quarterly revenue of $249,040.00 and a net loss of $-1,919,241.00, reflecting unprofitable operations. The 10% shareholder's cross-ticker track record shows 14 prior buys versus 6 prior sells, though the timing and outcome quality of those trades relative to this ticker are not measurable in the data provided.

Director Wurth Douglas Clark purchases 12,500 shares of BJDX at $2.00 in private placement as stock trades near 52-week lows.

Director Wurth Douglas Clark acquired 12,500 shares at $2.00 per share through a private placement structure on 2026-03-14, expanding his holdings from 108 to 12,608 shares. However, the FLAG designation indicates this transaction is a non-discretionary PIPE or registered direct offering allocation, not an open-market purchase driven by insider conviction. The current stock price of $1.72 is -89.7% from the 52-week high of $16.68, and the company is fundamentally distressed: revenue stands at $249,040.00 with net income of $-1,919,241.00 and market cap of only $1,779,709.80. The 30-day price decline of -14.0% and 90-day decline of -36.1% reflect deteriorating market sentiment. Because this is a structured private placement rather than a discretionary buy decision, the transaction should not be interpreted as insider conviction that value has emerged at depressed levels.

BJDX CEO Indranil purchased 12,500 shares at $2.00 in non-discretionary private placement; stock now trades at $1.72, down 89.7% from 52-week high.

Dey Indranil (President and CEO) purchased 12,500 shares of Bluejay Diagnostics at $2.00 on 2026-03-14, raising his holdings from 22 shares to 12,522 shares. However, this transaction is a private placement—not a discretionary open-market purchase—and therefore cannot be interpreted as a buying signal driven by insider conviction. The stock has declined sharply: the current price of $1.72 is 89.7% below the 52-week high of $16.68, and the company remains unprofitable with a net income of $-1.9M against revenue of $249.0K. Given the structured nature of the placement and the company's weak financial position, investors should focus on the underlying business fundamentals rather than attributing strategic meaning to the timing or sizing of this purchase.

Director Donald R Chase buys 12,500 shares of BJDX via private placement at $2.00, now down 14.0% in 30 days amid -89.7% from 52-week high.

Donald R Chase, a Director, purchased 12,500 shares at $2.00 as a private placement, not a discretionary open-market transaction. The acquisition increased his holdings from 25 shares to 12,525 shares. However, this transaction should not be interpreted as a conviction-driven buying signal given its non-discretionary nature. The stock has deteriorated substantially since the purchase: the current price of $1.72 is -89.7% from the 52-week high of $16.68, and the stock declined -14.0% over the past 30 days. The company's fundamentals remain deeply troubled, with net income of $-1.9M against quarterly revenue of $249.0K, and a market cap of only $1.8M, indicating severe operational stress and minimal equity value.

Director Fred S Zeidman purchases 12,500 shares of BJDX at $2.00 via private placement; stock down -89.7% from 52-week high.

Director Fred S Zeidman acquired 12,500 shares at $2.00 on 2026-03-14 through a private placement structure, meaning this transaction is not a discretionary open-market purchase. The stock has deteriorated significantly, currently trading at $1.72, down -89.7% from its 52-week high of $16.68, and down -36.1% over the past 90 days. The company's fundamentals remain stressed: latest quarterly revenue was $249.0K while net income was $-1.9M, with the company unprofitable over its most recent full fiscal year. The combination of structured equity allocation, severe stock decline, and ongoing losses suggests this was likely part of a financing event rather than a reflection of near-term business trajectory.

Director Svetlana Dey bought 12,500 shares of BJDX at $2.00 on 2026-03-14 via private placement; stock now $1.72.

Svetlana Dey, a Director, purchased 12,500 shares at $2.00 for a total value of $25,000.00 on 2026-03-14, raising her stake to 12,501 shares from 1 share pre-transaction. However, this transaction is a private placement, not a discretionary open-market purchase, and therefore should not be interpreted as a buying signal driven by insider conviction. The current stock price of $1.72 sits -89.7% from the 52-week high of $16.68 and is down 14.0% over the past 30 days, while Bluejay Diagnostics' latest quarter shows a loss of $-1.9M on revenue of $249.0K, with a market cap of only $1.8M. The company remains unprofitable and severely distressed, making this directive-participation transaction a structural necessity rather than a positive signal about near-term prospects.